You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 5, 2024

Claims for Patent: 9,382,217


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,382,217
Title:Modulators of sphingosine phosphate receptors
Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.
Inventor(s): Roberts; Edward (Fallbrook, CA), Rosen; Hugh (La Jolla, CA), Brown; Steven (San Diego, CA), Guerrero; Miguel A. (San Diego, CA), Peng; Xuemei (La Jolla, CA), Poddutoori; Ramulu (La Jolla, CA)
Assignee: The Scripps Research Institute (La Jolla, CA)
Application Number:14/311,825
Patent Claims: 1. A method of treatment of a malcondition in a patient having such malcondition, wherein the malcondition is multiple sclerosis, transplant rejection or adult respiratory distress syndrome, comprising administering to the patient an effective dose of a compound of formula (I), or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof: ##STR00261## wherein a dashed line signifies that a single bond or a double bond can be present, provided that there are two double bonds and three single bonds in the ring comprising A.sup.1, A.sup.2, and A.sup.3; A.sup.1 and A.sup.3 are N and A.sup.2 is O; L.sup.1 and L.sup.2 are each independently a bond; J independently at each occurrence is F, Cl, Br, I, OR', OC(O)N(R').sub.2, CN, CF.sub.3, OCF.sub.3, R', methylenedioxy, ethylenedioxy, N(R').sub.2, SR', SOR', SO.sub.2R', SO.sub.2N(R').sub.2, SO.sub.3R', C(O)R', C(O)C(O)R', C(O)CH.sub.2C(O)R', C(S)R', C(O)OR', OC(O)R', OC(O)OR', C(O)N(R').sub.2, OC(O)N(R').sub.2, C(S)N(R').sub.2, (CH.sub.2).sub.0-2NHC(O)R', N(R')N(R')C(O)R', N(R')N(R')C(O)OR', N(R')N(R')CON(R').sub.2, N(R')SO.sub.2R', N(R')SO.sub.2N(R').sub.2, N(R')C(O)OR', N(R')C(O)R', N(R')C(S)R', N(R')C(O)N(R').sub.2, N(R')C(S)N(R').sub.2, N(COR')COR', N(OR')R', C(.dbd.NH)N(R').sub.2, C(O)N(OR')R', or C(.dbd.NOR')R', wherein R' is independently at each occurrence hydrogen or an alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl wherein any alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is substituted with 0-3 J; R.sup.5 a group of formula a-i ##STR00262## mono- or pluri-substituted with J, wherein a wavy line indicates a point of attachment; R.sup.6 is phenyl mono- or pluri-substituted with J.

2. The method of claim 1 wherein the malcondition is transplant rejection or adult respiratory distress syndrome.

3. The method of claim 1 wherein the malcondition is multiple sclerosis.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.